Trametinib Monotherapy for the Treatment of Brain Metastasis From Non-small-cell Lung Cancer: a Case Report

Abstract Background: BRAF mutation mostly was observed in lung adenocarcinoma, accounting for about 4.9%. It mainly includes V600E mutation and other rare mutations, among which non-V600E positive accounted for about 43.3%. Case presentation: We report a case with postoperative recurrent NSCLC with brain metastasis and multiple lymph nodes metastasis, who had developed hemiplegia. The gene mutation was positive for BRAF non-V600E and a partial response was observed despite brain and multiple lymph nodes lesions after trametinib monotherapy. Conclusion: Our case shows that trametinib could potentially be a promising therapeutic agent for chemotherapy-refractory BRAF non-V600E mutant NSCLC patients.